Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 16 Feb 2022 Status changed from not yet recruiting to recruiting.
- 20 Jan 2022 Planned initiation date changed from 1 Nov 2021 to 1 Feb 2022.
- 19 Nov 2021 New trial record